Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 75 results:
Συντάκτης [ Τίτλος(Desc)] Τύπος Έτος
Φίλτρα: Συντάκτης is Bobos, Mattheos  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
G
Papadopoulou, K., Murray S., Manousou K., Tikas I., Dervenis C., Sgouros J., et al. (2018).  Genotyping and mRNA profiling reveal actionable molecular targets in biliary tract cancers.. Am J Cancer Res. 8(1), 2-15.
H
Kaiafa, G., Bobos M., Savopoulos C., Koutsokostas T., Kouskouras K., Kalogera-Fountzila A., et al. (2018).  Heart and lymphoma: An unusual case of secondary cardiac lymphoma manifested through presyncope and syncope episodes and atrial flutter.. Hellenic J Cardiol. 59(3), 182-185.
Fountzilas, G., Valavanis C., Kotoula V., Eleftheraki A. G., Kalogeras K. T., Tzaida O., et al. (2012).  HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.. J Transl Med. 10, 10.
Kalogiannidis, I., Petousis S., Bobos M., Margioula-Siarkou C., Topalidou M., Papanikolaou A., et al. (2014).  HER-2/neu is an independent prognostic factor in type I endometrial adenocarcinoma.. Arch Gynecol Obstet. 290(6), 1231-7.
I
Bobos, M., Hytiroglou P., Kostopoulos I., Karkavelas G., & Papadimitriou C. S. (2006).  Immunohistochemical distinction between merkel cell carcinoma and small cell carcinoma of the lung.. Am J Dermatopathol. 28(2), 99-104.
Stoyianni, A., Goussia A., Pentheroudakis G., Siozopoulou V., Ioachim E., Krikelis D., et al. (2012).  Immunohistochemical study of the epithelial-mesenchymal transition phenotype in cancer of unknown primary: incidence, correlations and prognostic utility.. Anticancer Res. 32(4), 1273-81.
Kourea, H. P., Kotoula V., Koutras A., Alexopoulou Z., Papaspirou I., Skarlos D. V., et al. (2015).  Impact of tumor angiogenic profile on the outcome of patients with metastatic breast carcinoma treated with weekly docetaxel. A Hellenic Cooperative Oncology Group (HeCOG) study.. Histol Histopathol. 30(9), 1129-41.
Kotoula, V., Bobos M., Kostopoulos I., Kaloutsi V., Koletsa T., Karayannopoulou G., et al. (2006).  In situ detection of hTERT variants in anaplastic large cell lymphoma.. Leuk Lymphoma. 47(8), 1639-50.
Vassilakopoulou, M., Togun T., Dafni U., Cheng H., Bordeaux J., Neumeister V. M., et al. (2014).  In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients.. PLoS One. 9(6), e99131.
Fountzilas, G., Bamias A., Kalogera-Fountzila A., Karayannopoulou G., Bobos M., Athanassiou E., et al. (2009).  Induction chemotherapy with docetaxel and cisplatin followed by concomitant chemoradiotherapy in patients with inoperable non-nasopharyngeal carcinoma of the head and neck.. Anticancer Res. 29(2), 529-38.
Kotoula, V., Bobos M., Vassilakopoulou M., Tsolaki E., Chrisafi S., Psyrri A., et al. (2015).  Intact or broken-apart RNA: an alternative concept for ALK fusion screening in non-small cell lung cancer (NSCLC).. Appl Immunohistochem Mol Morphol. 23(1), 60-70.
Lakis, S., Dimoudis S., Kotoula V., Alexopoulou Z., Kostopoulos I., Koletsa T., et al. (2016).  Interaction Between Beta-Catenin and EGFR Expression by Immunohistochemistry Identifies Prognostic Subgroups in Early High-risk Triple-negative Breast Cancer.. Anticancer Res. 36(5), 2365-78.
Fountzilas, G., Kotoula V., Pectasides D., Kouvatseas G., Timotheadou E., Bobos M., et al. (2013).  Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial.. PLoS One. 8(7), e69256.
M
Polychronidou, G., Kotoula V., Manousou K., Kostopoulos I., Karayannopoulou G., Vrettou E., et al. (2018).  Mismatch repair deficiency and aberrations in the Notch and Hedgehog pathways are of prognostic value in patients with endometrial cancer.. PLoS One. 13(12), e0208221.
Fountzilas, G., Kalogera-Fountzila A., Lambaki S., Wirtz R. M., Nikolaou A., Karayannopoulou G., et al. (2009).  MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer.. J Oncol. 2009, 305908.
Tirodimos, I., Bobos M., Kazakos E., Haidich A-B., Dardavessis T., Kostopoulos I., et al. (2014).  Molecular detection of Helicobacter pylori in a large Mediterranean river, by direct viable count fluorescent in situ hybridization (DVC-FISH).. J Water Health. 12(4), 868-73.
Murray, S., Karavasilis V., Bobos M., Razis E., Papadopoulos S., Christodoulou C., et al. (2012).  Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer.. J Exp Clin Cancer Res. 31, 77.
Gogas, H., Kotoula V., Alexopoulou Z., Christodoulou C., Kostopoulos I., Bobos M., et al. (2016).  MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer.. J Transl Med. 14(1), 136.
O
Lazaridis, G., Kotoula V., Vrettou E., Kostopoulos I., Manousou K., Papadopoulou K., et al. (2019).  Opposite Prognostic Impact of Single PTEN-loss and Mutations in Early High-risk Breast Cancer.. Cancer Genomics Proteomics. 16(3), 195-206.
P
Pavlakis, K., Bobos M., Batistatou A., Kotoula V., Eleftheraki A. G., Stofas A., et al. (2015).  p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumab.. Pathol Oncol Res. 21(2), 273-82.
Fountzilas, G., Kourea H. P., Bobos M., Televantou D., Kotoula V., Papadimitriou C., et al. (2011).  Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation.. Anticancer Res. 31(9), 3007-18.
Gogas, H., Pectasides D., Kostopoulos I., Lianos E., Skarlos D., Papaxoinis G., et al. (2010).  Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group.. Clin Breast Cancer. 10(3), 230-7.
Koumarianou, A., Karayannopoulou G., Gourgioti G., Batistatou A., Bobos M., Efstratiou I., et al. (2015).  PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients.. Cancer Chemother Pharmacol. 75(6), 1289-301.
Karavasilis, V., Kotoula V., Pentheroudakis G., Televantou D., Lambaki S., Chrisafi S., et al. (2013).  A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas.. J Neurol. 260(6), 1469-80.
Papaxoinis, G., Kotoula V., Giannoulatou E., Koliou G-A., Karavasilis V., Lakis S., et al. (2018).  Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping.. Med Oncol. 35(7), 101.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές